Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: BeammWave (Q3 Review) - Period of digestion

BeammWave

Redeye notes that BeammWave’s Q3 2025 report was in line with its EBITDA forecast, due to OPEX being 10% lower than expected, although capitalised costs were SEK0.9m below forecast. Following a capital raise that netted SEK79m, BeammWave holds a cash position of SEK93m. Redeye believes news flow will be limited ahead of the tape-out, as the company focuses on supporting existing customers, advancing its roadmap, and completing the chip's industrialisation. Redeye adjusts its Base Case from SEK12 to SEK11.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


BeammWave (Q3 Review) - Period of digestion

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.